The Heart Disease App segmentation by type classifies solutions according to development architecture and integration depth, a factor that influences cost structure and adoption speed. Native apps, built for iOS or Android, dominate with an estimated 40 % share because they leverage device‑specific sensors and deliver superior performance, justifying premium pricing. Web‑based platforms, accessible through browsers, represent roughly 20 % of the market; their cross‑platform reach lowers entry barriers but limits real‑time data capture. Hybrid solutions combine native shells with web content, accounting for about 15 % as they balance development efficiency with moderate functionality. Wearable‑integrated applications, which sync directly with smartwatches or patches, hold a 15 % slice, driven by the growing ecosystem of biometric devices and associated B2B contracts. AI‑driven apps, employing machine‑learning diagnostics and predictive analytics, occupy the remaining 10 % and command higher margins due to their proprietary algorithms. Collectively, these type categories map the technology‑driven taxonomy that underpins the Heart Disease App market’s revenue distribution.